The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) Regulations 2004

Changes over time for: SCHEDULE 2

Alternative versions:

Changes to legislation:

The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) Regulations 2004, SCHEDULE 2 is up to date with all changes known to be in force on or before 06 November 2024. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations.

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. Changes and effects are recorded by our editorial team in lists which can be found in the ‘Changes to Legislation’ area. Where those effects have yet to be applied to the text of the legislation by the editorial team they are also listed alongside the legislation in the affected provisions. Use the ‘more’ link to open the changes and effects relevant to the provision you are viewing.

View outstanding changes

Changes and effects yet to be applied to Schedule 2:

Sch. 2 words inserted by S.I. 2019/777 reg. 10(2)(a)(i) (This amendment not applied to legislation.gov.uk. Reg. 10 omitted immediately before IP completion day by virtue of S.I. 2020/1348, regs. 1, 9)
Sch. 2 words omitted by S.I. 2024/1065 reg. 2(3)(b)
Sch. 2 words substituted by S.I. 2019/777 reg. 10(2)(a)(ii) (This amendment not applied to legislation.gov.uk. Reg. 10 omitted immediately before IP completion day by virtue of S.I. 2020/1348, regs. 1, 9)
Sch. 2 table words substituted by S.I. 2024/1065 reg. 2(3)(a)

Changes and effects yet to be applied to the whole Instrument associated Parts and Chapters:

Whole provisions yet to be inserted into this Instrument (including any effects on those provisions):

reg. 1A inserted by S.I. 2024/1065 reg. 2(2)

Regulation 3

SCHEDULE 2E+WDRUGS [F1OR] MEDICINES TO BE ORDERED ONLY IN CERTAIN CIRCUMSTANCES

Textual Amendments

F1Word in Sch. 2 heading substituted (14.2.2014) by The National Health Service (General Medical Services Contracts) (Prescription of Drugs Etc.) (Wales) (Amendment) Regulations 2014 (S.I. 2014/109), regs. 1(1), 2(2)(a)

Commencement Information

I1Sch. 2 in force at 1.4.2004, see reg. 1(1)

Column 1	Column 2	Column 3
Drugs	Patient	Condition
In this Schedule— F2... [F3“at-risk” means in relation to a patient, a patient who— (a) has chronic respiratory disease (including asthma and chronic obstructive pulmonary disease); (b) has significant cardiovascular disease, excluding a patient who has hypertension only; (c) has chronic renal disease; (d) is immunocompromised; (e) has diabetes mellitus; (f) has chronic liver disease; or (g) has chronic neurological disease;] F2... “EEA Agreement” means the Agreement on the European Economic Area signed at Oporto on 2nd May 1992(3) as adjusted by the Protocol signed at Brussels on 17th March 1993(4) and as amended so far as is relevant to these Regulations, by Decision of the EEA Joint Committee No 7/94 of 21st March 1994(5); “EEA State” means a State which is a contracting party to the EEA Agreement or Switzerland. [F4“general medical practitioner” means a medical practitioner whose name is included in the General Practitioner Register, kept by the General Medical Council under section 2 of the Medical Act 1983;] [F4“GnRH analogue” means gonadotrophin-releasing hormone, a medicinal product that consists of or contains buserelin, gonadorelin, goserelin, leuprorelin acetate, nafarelin or triptorelin;] [F5“Pandemic influenza” means influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza;] [F6“patient” has the same meaning as in the [F7National Health Services (General Medical Service Contracts) (Wales) Regulations 2023];] [F6“residential care establishment” means a place where persons reside on a long-term basis in order to receive continuing care.]
Clobazam	Any patient	Treatment of epilepsy
F8. . .	F8. . .	F8. . .
[F9GnRH analogue]	[F10(1) Any patient who is aged 18 or over. (2) Any patient who is aged under 18 to whom the general medical practitioner is providing treatment under the contract which does not include treatment for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination of both. (3) Any patient who is aged under 18, and who— (a)before 19 July 2024, started a course of treatment with a GnRH analogue for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination of both, and in this context, a person is treated as having started a course of treatment with a GnRH analogue if, on or after 3 December 2023, that person was issued with a NHS or private prescription for a GnRH analogue, whether or not the prescription has been dispensed or the prescribed GnRH analogue has been taken by that person before 19 July 2024; or (b)is being treated with a GnRH analogue as part of a National Institute for Health and Care Research clinical trial related to treatment with a GnRH analogue for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination of both.]	[F11(1) Treatment for any purpose. (2) Treatment for any purpose other than treatment for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination of both. (3) Treatment for the purpose of puberty suppression in respect of gender dysphoria, gender incongruence or a combination of both.]
Locabiotal Aerosol	Any patient	Treatment of infections and inflammation of the oropharynx
Niferex Elixir 30ml Paediatric Dropper Bottle	Infants born prematurely	Prophylaxis and treatment of iron deficiency
Nizoral Cream	Any patient	Treatment of seborrhoeic dermatitis and pityriasis versicolor
[F12Oseltamivir (Tamiflu)	[F13(1) A patient F14... who is at clinical risk or a patient who is pregnant or aged 65 years or over, or who is aged under 65 years and is at risk of developing medical complications for influenza, where— (a)the Welsh Ministers have notified general medical practitioners that the influenza virus is circulating in the community; (b)the patient has an influenza-like illness; and (c)the patient can start therapy within 48 hours of the onset of symptoms. (2) A patient F14... who is at clinical risk or a patient who is pregnant or aged 65 years or over, or who is aged under 65 years and is at risk of developing medical complications for influenza, where— (a)it has been determined in accordance with a community based virological surveillance scheme that influenza A or influenza B is circulating in the locality in which the patient resides or is present or was present at the time that the virus was circulating; (b)the patient has an influenza-like illness; and (c)the patient can start therapy within 48 hours of the onset of symptoms. (3) Any patient suffering from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Welsh Minsters.	Treatment of influenza
[F12Oseltamivir (Tamiflu)	(4) A patient F14... who is at clinical risk or a patient who is pregnant or aged 65 years or over, where— (a)the Welsh Ministers have notified general medical practitioners that the influenza virus is circulating in the community; (b)the patient has been exposed to an influenza-like illness through being in close contact with someone with whom he lives who is or has been suffering from an influenza-like illness; (c)the patient is not effectively protected by vaccination against influenza because— (i)he has not been vaccinated because vaccination is contraindicated; (ii)he has not been vaccinated since the previous influenza season; (iii)he has been vaccinated but it has yet to take effect; or (iv)he has been vaccinated but the vaccine is not well matched to the strain of influenza circulating in the locality in which the patient resides or is or has been present; (d)the patient lives in a residential care establishment and another resident or member of staff of the establishment has an influenza-like illness; and (e)the patient can start prophylaxis within 48 hours of exposure to an influenza-like illness. (5) A patient F14... who is at clinical risk or a patient who is pregnant or aged 65 years or over, where— (a)it has been determined in accordance with a community based virological surveillance scheme that influenza A or influenza B is circulating in the locality in which the patient resides or is present or was present at the time that the virus was circulating; (b)the patient has been exposed to an influenza-like illness through being in close contact with someone with whom he lives who is or has been suffering from an influenza-like illness; (c)the patient is not effectively protected by vaccination against influenza because— (i)he has not been vaccinated because vaccination is contraindicated; (ii)he has not been vaccinated since the previous influenza season; (iii)he has been vaccinated but it has yet to take effect; or (iv)he has been vaccinated but the vaccine is not well matched to the strain of influenza circulating in the locality in which the patient resides or is or has been present; (d)the patient lives in a residential care establishment and another resident or member of staff of the establishment has an influenza-like illness; and (e)the patient can start prophylaxis within 48 hours of exposure to an influenza-like illness. (6) Any patient at risk from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Welsh Ministers.	Prophylaxis of infinfluenza]]
The following drugs for the treatment of erectile dysfunction— Alprostadil F15... [F16Avanafil] F17... F18... F17... F19... Sildenafil F20... Tadalafil F21... F17... F19... Vardenafil F22...	[F23(1) The following patients with erectile dysfunction—] (a)a man with erectile dysfunction who on 14th September 1998 was receiving a course of treatment under the Act, the National Health Service (Scotland) Act 1978(1) or the Health and Personal Social Services (Northern Ireland) Order 1972(2) for this condition with any of the following drugs— Alprostadil (Caverject), (MUSE), (Viridal) Apomorphine Hydrochloride (Uprima) Moxisylyte Hydrochloride Assembly (Erecnos) Sildenafil (Viagra) Tadalafil (Cialis) Thymoxamine Hydrochloride (Erecnos); or [F24(b) a man who is a national of an EEA State who— (i)immediately before IP completion day was entitled to treatment by virtue of Article 7(2) of Council Regulation 1612/68 as extended by the EEA Agreement or was entitled to treatment by virtue of any other enforceable EU right, (ii)has erectile dysfunction and was on 14th September 1998 receiving a course of treatment under a national health insurance system of an EEA State for that condition with any of the drugs listed in sub-paragraph (a), and (iii)immediately before IP completion day was receiving a course of treatment as part of the health service for the condition mentioned in paragraph (ii) of this sub-paragraph with any of the drugs listed in sub-paragraph (a), or] [F25(c) a man who is not a national of an EEA State but who is the member of the family of such a national and who— (i)immediately before IP completion day had an enforceable EU right to be treated no less favourably than the national in the provision of medical treatment, (ii)has erectile dysfunction and was on 14th September 1998 receiving a course of treatment for that condition with any of the drugs listed in sub-paragraph (a), and (iii)immediately before IP completion day was receiving a course of treatment as part of the health service for the condition mentioned in paragraph (ii) of this sub-paragraph with any of the drugs listed in sub-paragraph (a), or] (d)a man who is suffering from any of the following— diabetes multiple sclerosis parkinson’s disease poliomyelitis prostate cancer severe pelvic injury single gene neurological disease spina bifida spinal cord injury; or (e)a man who is receiving treatment for renal failure by dialysis; or (f)a man who has had the following surgery — prostatectomy radical pelvic surgery renal failure treated by transplant [F26(g)a man who has been diagnosed as suffering severe distress resulting from erectile dysfunction where the assessment has been made by a specialist service or GP under arrangements made with a Local Health Board to provide such assessments][F27;	Treatment of erectile dysfunction
	(2) Any patient]	[F28Treatment of a condition other than erectile dysfunction, in respect of which the drug ordered is in receipt of a UK or EU marketing authorisation for the treatment of that condition]
[F12Zanamivir (Relenza)	[F29(1) A patient who is aged 5 years or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, or who is aged under 65 years and is at risk of developing medical complications from influenza, where— (a)the Welsh Ministers have notified general medical practitioners that the influenza virus is circulating in the community; (b)the patient has an influenza-like illness; and (c)in the case of a patient— (i)who has attained the age of 5 years but not the age of 13 years, that patient can start therapy within 36 hours of the onset of symptoms; (ii)who is aged 13 years or over, that patient can start therapy within 48 hours of the onset of symptoms. (2) A patient who is aged 5 years or over and who is at clinical risk or a patient who is pregnant or aged 65 years or over, or who is aged under 65 years and is at risk of developing medical complications from influenza where— (a)it has been determined in accordance with a community based virological surveillance scheme that influenza A or influenza B is circulating in the locality in which the patient resides or was present at the time that the virus was circulating; (b)the patient has an influenza-like illness; and (c)in the case of a patient— (i)who has attained the age of 5 years but not the age of 13 years, that patient can start therapy within 36 hours of the onset of symptoms; (ii)who is aged 13 years or over, that patient can start therapy within 48 hours of the onset of symptoms.	Treatment of influenza
[F12Zanamivir (Relenza)	Any patient at risk of or suffering from influenza during an outbreak of pandemic influenza (influenza caused by a new virus subtype that has an increased and sustained transmission during a global outbreak of influenza), where the drug is ordered under arrangements for the distribution of the drug free of charge which are approved by the Welsh Ministers.	Prophylaxis or treatment of influenza]]